SinoMab BioScienceのRPE
SinoMab BioScienceのRPEは何ですか。
SinoMab BioScience LimitedのRPEは-7.86¥です。
RPEの定義は何ですか。
従業員1人当たりの収益（RPE）は、収益を組織の従業員の数で割ったものです。
HKSEのセクタHealth CareにおけるRPEの企業と比べるSinoMab BioScience
SinoMab BioScienceは何をしますか。
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
SinoMab BioScienceと類似のrpe
- Faron Pharmaceuticals OyのRPEは-19.60€です。
- Idera PharmaceuticalsのRPEは-15.47$です。
- Applied TherapeuticsのRPEは-12.33$です。
- Phunware IncのRPEは-10.81$です。
- Altisource Asset Management CorpのRPEは-10.67$です。
- Neueon TowersのRPEは-8.00₨です。
- SinoMab BioScienceのRPEは-7.86¥です。
- Hindustan MotorsのRPEは-4.43₨です。
- Lithium AmericasのRPEは-4.39$です。
- Propell LtdのRPEは-4.35AUD$です。
- Allied Hotel PropertiesのRPEは-4.10CAD$です。
- Home Point CapitalのRPEは-3.16$です。
- FluroTechのRPEは-2.99CAD$です。